C4 Therapeutics Inc. (CCCC)
C4 Therapeutics Statistics
Share Statistics
C4 Therapeutics has 70.59M shares outstanding. The number of shares has increased by 2.9% in one year.
| Shares Outstanding | 70.59M |
| Shares Change (YoY) | 2.9% |
| Shares Change (QoQ) | 1.8% |
| Owned by Institutions (%) | 91.96% |
| Shares Floating | 56.7M |
| Failed to Deliver (FTD) Shares | 1.62K |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 9.28M, so 13.15% of the outstanding shares have been sold short.
| Short Interest | 9.28M |
| Short % of Shares Out | 13.15% |
| Short % of Float | 16.31% |
| Short Ratio (days to cover) | 4.72 |
Valuation Ratios
The PE ratio is -2.12 and the forward PE ratio is -3.24. C4 Therapeutics's PEG ratio is -0.69.
| PE Ratio | -2.12 |
| Forward PE | -3.24 |
| PS Ratio | 13.51 |
| Forward PS | 8.9 |
| PB Ratio | 1.14 |
| P/FCF Ratio | -2.58 |
| PEG Ratio | -0.69 |
Enterprise Valuation
C4 Therapeutics Inc. has an Enterprise Value (EV) of 224.85M.
| EV / Earnings | -1.7 |
| EV / Sales | 10.83 |
| EV / EBITDA | -1.84 |
| EV / EBIT | -1.62 |
| EV / FCF | -2.07 |
Financial Position
The company has a current ratio of 6.34, with a Debt / Equity ratio of 0.29.
| Current Ratio | 6.34 |
| Quick Ratio | 6.34 |
| Debt / Equity | 0.29 |
| Total Debt / Capitalization | 22.38 |
| Cash Flow / Debt | -1.51 |
| Interest Coverage | -101.26 |
Financial Efficiency
Return on equity (ROE) is -0.54% and return on capital (ROIC) is -44.27%.
| Return on Equity (ROE) | -0.54% |
| Return on Assets (ROA) | -0.35% |
| Return on Capital (ROIC) | -44.27% |
| Revenue Per Employee | 143.14K |
| Profits Per Employee | -913.74K |
| Employee Count | 145 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.28M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -75.43% in the last 52 weeks. The beta is 2.96, so C4 Therapeutics's price volatility has been higher than the market average.
| Beta | 2.96 |
| 52-Week Price Change | -75.43% |
| 50-Day Moving Average | 3.55 |
| 200-Day Moving Average | 5.02 |
| Relative Strength Index (RSI) | 30.7 |
| Average Volume (20 Days) | 1.89M |
Income Statement
In the last 12 months, C4 Therapeutics had revenue of 20.76M and earned -132.49M in profits. Earnings per share was -2.67.
| Revenue | 20.76M |
| Gross Profit | -96.95M |
| Operating Income | -139.03M |
| Net Income | -132.49M |
| EBITDA | -122.1M |
| EBIT | -139.03M |
| Earnings Per Share (EPS) | -2.67 |
Balance Sheet
The company has 126.59M in cash and 70.98M in debt, giving a net cash position of 55.61M.
| Cash & Cash Equivalents | 126.59M |
| Total Debt | 70.98M |
| Net Cash | 55.61M |
| Retained Earnings | -528.38M |
| Total Assets | 376.06M |
| Working Capital | 229.94M |
Cash Flow
In the last 12 months, operating cash flow was -106.84M and capital expenditures -1.71M, giving a free cash flow of -108.55M.
| Operating Cash Flow | -106.84M |
| Capital Expenditures | -1.71M |
| Free Cash Flow | -108.55M |
| FCF Per Share | -2.19 |
Margins
Gross margin is -467.09%, with operating and profit margins of -669.84% and -638.34%.
| Gross Margin | -467.09% |
| Operating Margin | -669.84% |
| Pretax Margin | -632.17% |
| Profit Margin | -638.34% |
| EBITDA Margin | -588.28% |
| EBIT Margin | -669.84% |
| FCF Margin | -522.96% |
Dividends & Yields
CCCC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -98.89% |
| FCF Yield | -56.95% |
Analyst Forecast
The average price target for CCCC is $13, which is 381.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $13 |
| Price Target Difference | 381.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -1.49 |
| Piotroski F-Score | 4 |